Log in to save to my catalogue

EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wi...

EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wi...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1660406062

EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab

About this item

Full title

EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab

Publisher

Berlin/Heidelberg: Springer Berlin Heidelberg

Journal title

Journal of cancer research and clinical oncology, 2014-05, Vol.140 (5), p.737-748

Language

English

Formats

Publication information

Publisher

Berlin/Heidelberg: Springer Berlin Heidelberg

More information

Scope and Contents

Contents

Introduction
Cetuximab is a monoclonal epidermal growth factor receptor (EGFR)-targeting antibody, used in the treatment of colon cancer.
KRAS
mutation status is strongly predictive of cetuximab efficacy, but more predictive factors are needed for better patient selection. PTEN is a downstream inhibitor of the EGFR pathway and has been eva...

Alternative Titles

Full title

EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_1660406062

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1660406062

Other Identifiers

ISSN

0171-5216

E-ISSN

1432-1335

DOI

10.1007/s00432-014-1626-2

How to access this item